Wei Chen

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.4K citations · Full text

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

Nawal Al Kaabi, Yuntao Zhang, Shengli Xia et al. · JAMA · 2021 · 818 citations · Full text

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang et al. · The Lancet Infectious Diseases · 2021 · 291 citations · Full text

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 230 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Alie Wurie, Lihua Hou et al. · The Lancet · 2016 · 198 citations

Vaccination, Vaccine Safety, Vaccine Development +6